The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.

Related News Articles

Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
Eligible organizations can apply through May 6 for up to $1 million each for a three-year period to expand opioid and other substance use disorder services in…
Insights and Analysis
Birmingham VA Medical Center’s weekly, 90-minute shared medical appointments help veterans address opioid reliance.